SOURCE: Serenex

April 12, 2007 09:00 ET

Serenex Presents Ability of Proprietary Discovery Platform to Identify Novel, Orally Active Hsp90 Inhibitors, at AACR

DURHAM, NC -- (MARKET WIRE) -- April 12, 2007 -- Serenex, Inc., an integrated oncology-focused drug discovery and development company, announced today that Steven Hall, Ph.D., Senior VP Research and Development, will present at the American Association for Cancer Research Annual Meeting 2007. Dr. Hall's presentation will highlight the ability of Serenex's proprietary discovery platform to rapidly and efficiently identify novel small molecule scaffolds of Hsp90 inhibitors with improved pharmaceutical properties.

Dr. Hall's presentation will take place at 11:55 am on Tuesday, April 17 at the Los Angeles Convention Center. Serenex's proprietary technology platform increases the quality, speed and overall efficiency of drug discovery by generating compound selectivity information against thousands of targets within key protein families. The ability to profile individual compounds and compound libraries simultaneously against thousands of native proteins has led to the identification of potent, selective Hsp90 inhibitors.

The compounds selected by Serenex for development using this technology have significant advantages over other Hsp90 inhibitors in development. Other products in development have been modified from three naturally-derived chemical scaffolds; geldanamycin, purine and radicicol, primarily because Hsp90 is difficult to target for small molecule screening using conventional methodologies. As demonstrated in this presentation, Serenex's platform technology has enabled the company to identify novel small molecule scaffolds of Hsp90 inhibitors, which have unique and improved pharmaceutical properties compared to other products in development. Serenex's lead Hsp90 inhibitor, SNX-5422, is scheduled to begin clinical trials in the second quarter of 2007.

About Serenex

Serenex is an integrated oncology-focused drug discovery and development company. Serenex's lead program, SNX-1012, a product for chemotherapy and radiation-induced oral mucositis in solid tumor patients, is scheduled to complete phase 2 clinical trials in early 2008. Oral mucositis, which represents a large and underserved market, frequently causes clinicians to interrupt therapy which directly leads to decreased rates of efficacy. Additionally, Serenex has a novel pre-clinical small molecule inhibitor of Heat Shock Protein 90 (Hsp90) which is scheduled to begin clinical trials in the second quarter of 2007. Hsp90 is a central protein responsible for chaperoning a large number of oncogenic proteins (such as Her2 and Raf) that are necessary to support cancer cell survival and growth. Serenex's pipeline is powered by a proprietary high throughput screening platform which enables the company to profile compounds, en masse, against thousands of important therapeutic and toxicity targets. Website:

Contact Information


    Ian Howes
    CFO & Sr. V.P. Corporate Development
    Serenex, Inc.
    Email Contact

    Michelle Linn
    Linnden Communications
    Email Contact